Table 1B.
Unapproved Tyrosine Kinase Inhibitors with Late-Phase Clinical Evidence in RAIR DTC
| Agent | Indication | Trial | Number of Patients | ORR | Reference |
|---|---|---|---|---|---|
| Vandetanib | RAIR DTC | Phase 2 RCT | 145 | 8% vs. 5% | Leboulleux et al 2012 [48,49] |
| Cabozantinib | RAIR DTC | Phase 1 | 15 | 53% | Cabanillas et al 2014 [50] |
| Phase 2 pending (NCT02041260, NCT01811212) [51,52] | |||||
| Sorafenib | MTC | Phase 2 | 16 | 6% | Lam et al 2010[53] |
| MTC | Phase 2 | 15 | 25% | Ahmed et al 2010 [54] | |
| MTC | Phase 2 pending (NCT00390325) [55] | ||||
| Lenvatinib | MTC | Phase 2 | 59 | 36% | Schlumberger et al 2009 [56] |
| Axitinib | Mixed | Phase 2 | 45 RAIR DTC, 11 MTC | 30% | Locati et al 2008 [34] |
| Mixed | Phase 2 | 45 RAIR DTC, 6 MTC | 35% | Cohen et al 2014 [35] | |
| Pazopanib | RAIR DTC | Phase 2 | 37 | 49% | Bible et al 2010 [32] |
| MTC | Phase 2 | 35 | 14% | Bible et al 2014 [36] | |
| RAIR DTC | Phase 2 pending (NCT01813136) [138] | ||||
| Sunitinib | RAIR DTC | Phase 2 | 23 | 26% | Bikas et al 2016 [37] |
| Mixed | Phase 2 | 27 RAIR DTC, 7 MTC | 31% | Carr et al 2010 [33] | |
| Mixed | Phase 2 pending (NCT00381641) [59] | ||||
*
Complete response in one patient